TIKOMED AB news
A new study with TikoMed’s platform lead clinical drug candidate ILB®, provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of Amyotrophic Lateral Sclerosis (ALS). The study was published in PLOS ONE today.
In a phase II study of ILB administered to patients with ALS for five weeks, the progression of
Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation.
The collaboration will support TikoMed’s clinical development, regulatory and commercial strategies. IQVIA brings together deep therapeutic
New study results for Tikomed’s platform lead drug candidate ILB® in the treatment of patients with amyotrophic lateral sclerosis (ALS), have now been published in the Journal of Personalized Medicine. The data revealed a significant normalization of the serum levels of several key metabolites in addition to a significant improvement of patients’ clinical conditions for the duration of the ILB® treatment period. The treatment response appears to b
TIKOMED, a specialty pharmaceutical company developing an infusion product for improving the outcome in cell therapies, today announced that the first patient has been treated in TIKOMED’s ongoing Phase II international, multicenter study – NNCIT-02.
In the NNCIT-02 study, brittle diabetes patients being transplanted with islets of Langerhans are treated with IBSOLVMIR® which has shown to be able to address the instant blood-mediated inflammatory reaction (IBMIR) occur
A new study on TIKOMED’s lead drug candidate, ILB®, was published in npj Regenerative Medicine today. The peer-reviewed data from rodent and human disease models showed that ILB® leads to tissue remodelling, reduced fibrosis and functional tissue regeneration – observations indicating the potential of ILB® to alleviate fibrotic diseases.
Professor Ann Logan, from the University of Warwick, leader of the research team and senior author of the publication, sa
Our Phase IIa clinical trial evaluating the safety, tolerability and possible efficacy of subcutaneous injections of ILB® in ALS is finalized and has been reported to the Swedish Medical Products Agency.
The results indicate that, for the variants of ALS and the given dose investigated in the study, ILB® seems to have beneficial clinical effects without significant side effects.
A clinical program involves four phases (I-IV) where each phas
A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.
“This very important result of the beneficial effect of ILB® on post-impact brain metabolism
TIKOMED, a Swedish privately-held biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to its lead drug candidate ILB® for the treatment of patients with amyotrophic lateral sclerosis (ALS) – a terminal, neurodegenerative disease where most patients die of respiratory muscle weakness in less than three to five years from symptom onset and for which there is yet no cure.
Orphan Drug Designation (ODD) in the European Union
TIKOMED, a Swedish privately-held biopharmaceutical company today announced that it has successfully completed a €5 million round of financing from current investors. The capital will primarily be used to support the ongoing clinical development program for ILB™ and IBSOLVMIR®, advancing the company’s position within the treatment of acute and degenerative neurological diseases and cell transplantation.
“We are delighted to have secured th